- Home
- ZYME
ZYME
Zymeworks Inc.
as 07-26-2024 4:00pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Upcoming Earnings Alert:
Get ready for potential market movements as Zymeworks Inc. ZYME prepares to release earnings report on 01 Aug 2024.
| Founded: | 2003 | Country: | Canada |
| Employees: | 275 | City: | MIDDLETOWN |
| Market Cap: | 751.6M | IPO Year: | 2017 |
| Target Price: | $12.67 | AVG Volume (30 days): | 639.3K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.02 - $13.14 | Next Earning Date: | 08-01-2024 |
| Revenue: | $50,464,000 | Revenue Growth: | -88.69% |
| Revenue Growth (this year): | 64.8% | Revenue Growth (next year): | -22.20% |
Stock Insider Trading Activity of Zymeworks Inc. (ZYME)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Astle Christopher | ZYME | SVP & Chief Financial Officer | Jan 5 '24 | Sell | $10.65 | 4,563 | $48,605.99 | 7,934 | SEC Form 4 |
| Astle Christopher | ZYME | SVP & Chief Financial Officer | Jan 5 '24 | Sell | $11.22 | 1,431 | $16,049.52 | 6,503 | SEC Form 4 |
| Moore Paul Andrew | ZYME | Chief Scientific Officer | Jan 5 '24 | Sell | $10.65 | 7,460 | $79,465.41 | 9,706 | SEC Form 4 |
| Moore Paul Andrew | ZYME | Chief Scientific Officer | Jan 5 '24 | Sell | $11.22 | 2,339 | $26,233.29 | 7,367 | SEC Form 4 |
| Galbraith Kenneth | ZYME | Chair & CEO | Jan 5 '24 | Sell | $10.65 | 18,198 | $193,848.74 | 29,468 | SEC Form 4 |
| Galbraith Kenneth | ZYME | Chair & CEO | Jan 5 '24 | Sell | $11.22 | 5,706 | $63,996.21 | 23,762 | SEC Form 4 |
| Astle Christopher | ZYME | SVP & Chief Financial Officer | Dec 11 '23 | Sell | $9.13 | 886 | $8,089.27 | 1,997 | SEC Form 4 |
Latest Zymeworks Inc. News
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire
5 days ago
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
GlobeNewswire
16 days ago
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
GlobeNewswire
a month ago
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Simply Wall St.
a month ago
Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
GlobeNewswire
2 months ago
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
GlobeNewswire
2 months ago
Zymeworks Announces Participation in Upcoming Investor Conferences
Simply Wall St.
3 months ago
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Compare ZYME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.